CTOs on the Move

BZAM Cannabis

www.bzamheadquarters.com

 
Headquartered in Vancouver, BC, BZAM Cannabis is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

NeuLife Rehab

NeuLife Rehabilitation is a company that provides post-acute rehabilitation programs for clients with catastrophic injuries. Their goal is to assist clients in achieving successful outcomes and personal fulfillment so they can function as independently...

Access Healthcare Services

Access Healthcare Services, Inc. is a Nepean, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AdCare Health Systems

Founded in 1991, AdCare Health Systems, Inc. (NYSE MKT: ADK) is a leading provider of senior living and health care facility management, dedicated to providing the highest quality of healthcare services to the elderly. AdCare operates 46 facilities in Alabama, Arkansas, Georgia, Ohio, Oklahoma, North Carolina, Missouri and South Carolina, with approximately 4,700 beds in service. The facilities comprise 43 skilled nursing centers, three assisted living residences and one senior independent living facility. AdCare owns 24 of the skilled nursing centers and two of the assisted living facilities, with the others operated under long-term lease, consolidated variable interest entity, or management contract.

Lite Source Inc

Lite Source Inc is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.